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Background: Huntington’s disease (HD) is a monogenic disorder caused by an aberrant expansion of CAG repeats
in the huntingtin gene (HTT). Pathogenesis is associated with expression of the mutant (mHTT) protein in the CNS,
with its levels most likely related to disease progression and symptom severity. Since non-invasive methods to
quantify HTT in the CNS do not exist, measuring amount of soluble HTT in peripheral cells represents an important
step in development of disease-modifying interventions in HD.
Results: An ELISA assay using commercially available antibodies was developed to quantify HTT levels in complex
matrices like mammalian cell cultures lysates and human samples. The immunoassay was optimized using a
recombinant full-length HTT protein, and validated both on wild-type and mutant HTT species. The ability of the
assay to detect significant variations of soluble HTT levels was evaluated using an HSP90 inhibitor that is known to
enhance HTT degradation. Once optimized, the bioassay was applied to peripheral blood mononuclear cells
(PBMCs) from HD patients, demonstrating good potential in tracking the disease course.
Conclusions: The method described here represents a validated, simple and rapid bio-molecular assay to evaluate
soluble HTT levels in blood cells as useful tool in disease and pharmacodynamic marker identification for observational
and clinical trials.Background
Huntington’s disease is an inherited autosomal domin-
ant neurodegenerative disorder characterized by motor
dysfunction, psychiatric disturbances, and progressive
dementia [1,2]. HD is caused by an unstable CAG re-
peat expansion in the gene encoding huntingtin (HTT)
on chromosome 4, leading to an extended polygluta-
mine (polyQ) stretch in the amino terminus of the HTT
protein [3]; the disease is therefore associated with a
mutant form of the HTT protein that contains 36 or
more glutamine residues. The presence of pathologic
expanded HD alleles is detected by diagnostic testing in
compliance with the Standards and Guideline for Clin-
ical Genetics Laboratories; other scalable-throughput* Correspondence: lmassai@sienabiotech.it
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reproduction in any medium, provided the orscreening assay by PCR-MCA [4] or chimeric primed
PCR (TP-PCR) [5] are developed and represent an attract-
ive alternative to classical molecular screening method.
Pathogenesis arises mainly from mHTT expression, which
leads to the formation of toxic soluble protein oligomers
and insoluble aggregates [6,7], contributing to the disrup-
tion of multiple intracellular pathways involving mitochon-
drial dysfunction [8], oxidative stress [9], transcriptional
dysregulation [10], autophagy [11,12] and metabolic im-
pairment [13]. Nevertheless, loss of wild-type HTT func-
tion may also have a role in HD [14-16].
Several efforts are made to correlate the dysregulation of
these pathways [17-19] with HD, providing solid platforms
to describe disease progression. The pathology onset and
severity significantly correlate with polyQ length [20], al-
though environmental modulators and associated gene-
environment interactions also influence disease progression
[21,22]. Moreover HD is characterized by general brain at-
rophy and neuronal cell loss [23], which starts from theLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regions [24]. Whilst mHTT expression in the CNS [25] is
the primary pathological hallmark in HD development
[26], the presence of abnormalities in several other com-
partments [27] provide a source of accessible tissue for
HTT quantification potentially to monitor disease progres-
sion and treatment efficacy. Here, we report the develop-
ment of a robust and simple ELISA assay that is sensitive
enough to detect differences in endogenous HTT levels in
blood from HD patients at different stages of disease,
highlighting its potential suitability for monitoring both
disease progression and therapeutic intervention in clinical
trials.
Results
Protein purification and quality control (QC)
Recombinant human HTT full-length protein carrying a
3XFLAG tag at the N-terminus and a polyQ stretch of 138
glutamine residues (HTT-Q138) was produced using an
inducible cell clone 293/T-Rex® Q138-CRE-RL1 (RL1) ex-
pressing intracellular HTT protein upon doxycycline in-
duction [28]. To maximize yield and avoid significantFigure 1 Full-length HTT-Q138 purification and standard curve for HT
HTT-Q138 purification process (lane 1: molecular weight standard; lane 2: 3
post induction; lane 4: anti-FLAG affinity gel flow trough; lane 5–6: gel was
with anti-FLAG (lanes sequence as in panel A). Panel C, HTT-ELISA assay sta
vidually. Curve showed is a representative example of multiple assays.degradation of the protein, induction times ranging from
12 to 96 hours were tested on small scale samples. We
chose an induction time of 24 hours for the HTT-Q138
large scale preparation, since at that time HTT expression
was stable. Figure 1A shows a typical result of the protein
purification process. Purified HTT-Q138 showed an appar-
ent molecular weight of ~340 kDa in agreement with the
calculated value of 348 kDa. Recombinant protein was rec-
ognized by anti-FLAG antibody in cell lysate and efficiently
captured by the same antibody immobilized onto the resin.
Subsequently, it was eluted from the resin, by the compet-
ing FLAG-peptide; typically, we were able to obtain ~300
μg of HTT-Q138 from 1.2×109 cells with a purity of more
than 90%, as evaluated by Coomassie stained NuPAGE
gels. The identity of the purified protein was confirmed
by Western blotting using anti-HTT specific antibodies
(data not shown). Tandem mass spectrometry analysis
of purified protein samples, digested with three different
enzymes (trypsin, Glu-C and chymotrypsin), identified
1044 unique peptides of the protein, which corresponded
to a sequence coverage of 86% and confirmed the purity
of HTT-Q138.T-ELISA assay. Panel A, Gel coomassie staining of samples from the
0 μg RL1 cell lysate before induction; lane 3: 30 μg RL1 cell lysate 24 h
hes; lane 7–9: 5 μL of eluted fractions). Panel B, Western blot stained
ndard curve displays absorbance calibration values in duplicates indi-
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Several commercially-available antibodies (Table 1), raised
against epitopes that were not overlapping with the polyQ
region, were selected on the basis of their declared proper-
ties and literature description, with the aim of developing
an ELISA sandwich assay able to quantify HTT protein in
biological matrices (i.e. cell lysates or body fluids) irrespect-
ive of its polyQ expansion. The performance of each anti-
body as a capturer was assessed using purified HTT-Q138
as the standard protein and anti-FLAG-HRP conjugate as
the detection antibody. Signal to background reading ratios
were evaluated comparing four dilutions of each capture
antibody against the standard curve, composed of con-
centrations ranging up to 5000 pg/well. The 4E10 and
3E10 antibodies were the most efficient, detecting HTT
quantities up to 50 ng/well, reaching 18-fold signal-to-
background ratio at saturation. The same procedure was
then applied to select the best detection antibody. The
most suitable was EP867Y and this was chosen together
with 4E10 as the capture antibody to form the final HTT-
ELISA. Subsequently, the assay conditions were optimized
in terms of the concentrations of primary, secondary and
HRP-conjugated antibody, incubation times and blocking
agent to determine the maximally sensitive and stable assay
conditions. These were 4E10 at 1 μg/mL, EP867Y at 1 μg/
mL and blocking with BSA 1%. Under these conditions,
the assay showed a dynamic range of five orders of magni-
tude (from 0.15 pM up to 30 nM of HTT), with a 19-fold
signal-to-background ratio. Ten serial dilutions of HTT-
Q138were used to generate standard curves in all subse-
quent analyses. Assay validation has been performed using
ten independent experiments, obtaining intra-plate %CV
below 10%, inter-assay %CV lower than 20%, LLOQ (lower
limit of quantitation) of 2.7 fmol/well and accuracy within
a 10% error. In each case, the standard curve was fitted
with four-parameter sigmoid model and threshold for R
square above 0.99 was set as acceptance criterion. An ex-
ample of standard curve is presented in Figure 1C.
Mutant and wild type HTT quantification in mammalian
cell extracts
Total lysates of induced and non-induced RL1 cells,
were used to establish the sensitivity and specificity ofTable 1 Commercial antibodies tested
Antibodies tested
Name Host Antigen
3D6 Mouse, monoclonal aa 81-191
EP867Y Rabbit, monoclonal aa 511-588
D549 Rat, monoclonal aa 549-679
3E10 Mouse, monoclonal aa 997-1276
4E10 Mouse, monoclonal aa 1844-2131
8A4 Mouse, monoclonal aa 2703-2911the HTT-ELISA on complex matrices. Since we were inter-
ested in quantifying only the soluble protein, a centrifuga-
tion step in lysates preparation was introduced to avoid any
interference from HTT aggregates. This was adopted for all
subsequent analyses. HTT-Q138 expression induced by
24 hours treatment with 1 μg/mL doxycycline was detected
by our assay, showing an approximately 500-fold increase
in HTT protein expression by these cells (Figure 2A). We
also assessed the sensitivity of the assay for wild-type HTT
relative to the mutant form, even though both molecular
species should be detected with the same sensitivity (each
of the selected antibodies recognize HTT epitopes far from
the polyQ region, 4E10 at amino acids 1844–2131 and
EP867Y at 511–588). We therefore verified the antibodies
performance for the two proteins using total lysates of
HEK 293 cells transiently transfected with plasmids encod-
ing for 3XFLAG-full length HTT with either a stretch of
17 or 138 glutamine residues. 24 hours after transfection,
cell lysates were analyzed by Western blotting with anti-
HTT H7540 and by our HTT-ELISA assay (Figure 2B
and C). The quantification of soluble HTT levels was
in agreement with the densitometric quantification of
Western blot analysis of the same samples (Figure 2D),
demonstrating that the ELISA method was able to detect
wild-type and mutant protein with the same sensitivity.
Pharmacological assay validation
As inhibitors of HSP90 have been demonstrated to modu-
late mHTT steady state levels in cellular systems [29], we
decided to validate our assay by assessing the detection of
soluble HTT in complex matrices following pharmaco-
logical modulation. Firstly we verified that co-expression of
HSP90 with wild-type and mutant HTT significantly in-
creased the levels of HTT detected by the assay in total cell
lysates (Figure 3A). This effect is exerted at protein level,
as no increase in either HTT-Q138 or HTT-Q17 mRNA
was observed by real-time qPCR and paradoxically, HTT-
Q138 mRNA was reduced (Figure 3B). For pharmaco-
logical modulation, cells were treated for 24 hours with
NVP-AUY922, a small molecule known to be a potent
HSP90 inhibitor [30]. Upon modulation of HSP90 activity,
we observed a significant reduction in soluble HTT protein
irrespective of the presence of the expanded polyQ stretch
(Figure 3C). Interestingly this treatment not only reduced
the soluble protein, but also induced the expression of its
mRNA as shown by RT-PCR analysis (Figure 3D). In sum-
mary, the pharmacological validation of the assay demon-
strated its capacity to detect, in a significant manner, small
variations in soluble HTT levels induced by inhibition of
an enzyme modulating protein degradation.
HTT detection in blood cells
A bioassay designed to measure soluble HTT level mul-
tiple times over long periods of time in clinical trials
Figure 2 HTT-Q138 and HTT-Q17 quantification in mammalian cell lysates sample. Panel A, Fold-induction of HTT-Q138 expression
detected with ELISA assay in uninduced and induced RL1 cells. Panel B, HTT-ELISA analysis of HEK293 cells transfected with full-length HTT-Q17
and HTT-Q138. Panel C and D, Western blot and densitometry analysis of HTT-Q17 and HTT-Q138 transfected HEK293 cells. The blot was probed
with antibodies specific for HTT (HTT-H7540) and α-tubulin (loading control).
Figure 3 Pharmacological assay validation. Panel A and B, Effect of HSP90 overexpression on HTT protein (by ELISA) and gene (by RT-PCR)
respectively. Panel C and D, Effect of HSP90 inhibition by NVP-AUY922 on HTT protein (by ELISA) and gene (by RT-PCR) respectively. Readings are
normalized against Ctrl or DMSO as appropriate; statistical analyses are performed with two-way ANOVA followed by Bonferroni test for
multiple comparisons (* p < 0.05, ** p < 0.01 wrt Ctrl or DMSO).
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able material for analysis. Therefore, we chose PBMCs,
as they are easily obtained from a patient’s blood sample.
Preliminary experiments using lysates of fresh PBMCs
obtained from 6 mL of pooled rat blood allowed us
to measure HTT at a concentration of 0.25 ± 0.03 nM
(mean ± SD). This demonstrated that the sensitivity of
the assay was sufficient to quantify native protein using
100 μL/well of total lysate without using any sample en-
richment procedure. To verify the suitability of the assay
for the quantification of the HTT protein in specimens
similar to those commonly available in clinical trials, we
analyzed lysates from frozen human PBMC pellets. The
complete set of samples, five subjects of each group, in-
cluded healthy volunteers, premanifest and HD patients
at early, moderate and advanced disease-stage. To en-
sure assay reproducibility, in vitro aggregation of high
molecular weight HTT protein was prevented by pro-
cessing each PBMC sample as described in the Methods
section. Soluble HTT levels and total protein content
were subsequently measured and results were expressed
for each sample as ratio between HTT quantities and
total protein content (Figure 4). HTT quantification was
repeated in independent experiments, loading all the
samples to be compared on the same plate to avoid
inter-plate effects. The outcome of these series of experi-
ments clearly demonstrated that HD patients have sig-
nificantly lower levels of soluble HTT in their PBMCs
compared with healthy controls. This negative modula-
tion is even more evident when symptoms of the diseaseFigure 4 HTT detection in blood cells sample. Quantification by
HTT-ELISA on human PBMC total lysates from HD patients at different
disease stages, premanifest and healthy volunteers controls (HV).
Gene carrier samples were significantly different from healthy controls
(one-way ANOVA followed by Bonferroni test for multiple comparisons
wrt HV group, p < 0.001). Individual estimates and median values are
displayed in logarithmic scale.become manifest, suggesting altered HTT processing
and clearance [31,32] as the disease progresses.
Discussion
The site of the disease-causing mutation in the HTT
gene responsible for HD was identified twenty years ago
[33]. Since then, efforts have focused on the study of
HTT and its role in pathogenesis, identifying the etiology
of the disorder, treating and preventing motor symp-
toms, and managing a range of neurologic and behav-
ioral complications [34-36]. The investigation has been
challenging due to the high molecular weight of the
HTT protein, its heterologous expression, and the ten-
dency to aggregate [37-40]. Consequently, research has
been directed at truncated forms [41] instead of the full-
length protein. However, recent studies have started to
examine the presence of the native full-length protein in
human brain [42], leading to the generation of more
physiological models of HD pathology [43,44] and sug-
gesting that full length HTT may also be pathogenic in
HD [45,46], thus boosting pharmaceutical research into
drugs augmenting HTT clearance. The development of
the assay is driven by the necessity to quantify in a pre-
cise and sensitive way the full length HTT protein in
multiple biological matrices. During the development of
the assay, we were able to identify suitable sandwich de-
tection reagents from a wide selection of commercially
available monoclonal antibodies against different epi-
topes of the full-length HTT protein. Importantly, the
selected antibodies recognized not only the human HTT,
but also the rodent homologue, facilitating quantification
of the endogenous protein in animal models. Our ELISA
has been demonstrated to be capable of detecting both
the wild-type and mutant HTT protein with comparable
sensitivity and to be very robust as the assay has been
repeated over a period of more than two years, by differ-
ent operators using several antibody lots giving always
comparable results. The assay produced results in keep-
ing with published data detecting a pharmacological
modulation of HSP90 activity by means of its effect on
soluble HTT levels in cultured cells. The analysis of hu-
man samples indicates that levels of soluble HTT in
PBMC cells was quantifiable using our assay without
any need of enrichment and that it was possible to de-
tect different levels of the protein in healthy controls
compared to HD patients. In fact, the decline in soluble
HTT levels has already been shown to inversely cor-
relate with disease-related aggregated HTT [47]. Inter-
estingly, soluble HTT levels in premanifest mutation
carriers are closer to those in HD patients with manifest
disease than in healthy volunteers. We therefore specu-
late that the assay could be used as a valuable tool to
monitor HTT concentrations longitudinally and to assess
the efficacy of HTT lowering compounds in clinical
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the interest of HTT quantification in peripheral tissues,
only one assay, a TR-FRET for the detection of total and
mutant HTT, has been published [48-50]. This homoge-
neous assay employs non-commercial antibodies and
does not reveal differences in total HTT protein when
comparing HD patients with healthy controls. The dis-
crepancy of the results of the two assays could be ex-
plained in terms of different techniques, antibodies and
analytes solubilization procedures used.
Conclusions
The results presented here demonstrate that this HTT-
ELISA is able to reliably detect the variation of HTT
levels following pharmacological manipulation of an en-
zyme known to act on the steady-state levels of the pro-
tein. Further, it can differentiate between peripheral cells
isolated from healthy controls and HD patients at differ-
ent disease stages. This assay has recently been applied
in a phase 1b clinical study performed at different sites,
and represents a quick, easy and reliable tool to monitor
the effects of potential therapeutics for HD in observa-
tional and clinical trials.
Methods
Recombinant human huntingtin expression and
purification
The generation of recombinant 293/T-Rex® cells stably ex-
pressing, in a doxycyclin inducible manner, full-length
mutant HTT with a stretch of 138 glutamines 3×Flag
N-terminally tagged (T-Rex®-Q138-CRE-RL1), has been
described elsewhere [28]. For large scale purification,
12×108cells were grown in Dulbecco's Modified Eagle
Medium, D-MEM containing 10% Tetra-Free Fetal Bovine
Serum, 1% Pen/Strep, 1% G-Max (all from Gibco, Life
Technologies, Paisley, UK) supplemented with 0.25 mg/mL
Hygromycin (Life Technologies), 50 μg/mL Zeocin (Invivo-
Gen, San Diego, CA) and 5 μg/mL Blasticidin (Invivogen)
at 37°C, 5% CO2 in disposable 150 cm
2 polystyrene flasks.
Transgene expression was induced with doxycyclin (Sigma
Aldrich, St. Louis, MO, USA) at 1 μg/mL final concentra-
tion and cells were collected after 24 hours. Cellular pellets
were washed in PBS and lysed (10×106 cells/mL) by so-
nication in loading buffer (Tris 50 mM pH 7.4, NaCl
150 mM, EDTA 1 mM) supplemented with protease and
phosphatase inhibitors (Complete EDTA–free protease in-
hibitor cocktail, and PhosSTOP, phosphatase inhibitor
cocktail, Roche Diagnostic GmbH, Mannheim, Germany).
Total lysates were clarified by centrifugation at 1500 g for
5 minutes at 4°C. Typically, 10 mL of clarified lysates were
loaded, in batch mode, onto 1 mL of slurry anti-FLAG M2
affinity gel (Sigma Aldrich) equilibrated in loading buffer,
under moderate agitation, overnight at 4°C. Affinity gel
was then washed twice with washing buffer (Tris 20 mMpH 7.4, NaCl 100 mM containing protease inhibitor) and
HTT-Q138 protein was eluted in three 500 μL fractions of
loading buffer containing 150 ng/μL 3×FLAG peptide for
30 minutes at 4°C. Each fraction was analyzed by Nu-PAGE
on 3-8% Tris-Acetate gel (Life Technologies) followed by
Bio Safe Coomassie Blue G-250 (Bio-Rad Hercules, CA,
USA) staining and HTT identity was confirmed by Western
Blotting using anti N-terminal HTT H7540 and anti FLAG
antibodies. Protein concentration in eluted fraction was
determined using BCA kit (Piercenet, Thermo Scientific,
Rockford, USA) according to the manufacturer’s instructions.
Western blot analysis
Total protein lysates (35 μg) were loaded on 3–8% Tris-
acetate gels (Life Technologies) and transferred overnight
at 30 V to PVDF membranes (GE Healthcare, Europe
GmbH). Membranes were blocked in 3% NonFat Dry Milk
(NFDM) for 1 hour, washed with PBS-Tween 20 0.01%
and incubated with the appropriate antibody in 3% NFDM
(anti-FLAG at 1 μg/mL, anti-N-terminal HTT H7540 at
0.1 μg/mL and anti α-tubulin, clone DM1A, all from Sigma
Aldrich). HRP-conjugated secondary antibodies (Bio-Rad)
were diluted 1:30,000 in 3% NFDM and incubated for
1 hour at room temperature. ECL Prime substrate (GE
Healthcare) was used to develop chemiluminescent signal,
acquired using Versadoc 4000 (Bio-Rad) or Hyperfilm ECL
(GE Healthcare).
Transient transfection and treatments
HEK293 cells were grown in D-MEM containing 10%
FBS, 1% Pen/Strep, 1% G-Max (all from Gibco, Life
Technologies). 8×105 cells were seeded on MW6 plates
(Corning Life sciences Inc.) coated with 1% poli-D lysine
and after 24 hours transfected with 2 μg of total plasmid
DNA using Lipofectamine 2000 (Life Technologies) ac-
cording to manufacturer’s instructions. Plasmids carried
the same HTT sequence used for stable cell line gener-
ation, bearing a stretch of 17 or 138 glutamines and an
N-terminal 3XFLAG, under the control of CMV pro-
moter (HTT-Q17 and HTT-Q138, respectively). Control
wells were transfected with empty vector pcDNA 3.1
Zeo+ (Life Technologies). Medium was changed 4 hours
after transfection and NVP-AUY922 (Novartis Institutes
for Biomedical Research, Basel, Switzerland) in DMSO
was added with medium change at final concentration of
0.3 and 3 μM. Control wells were supplemented with
DMSO at the same concentration as test wells. Cells
were collected 24 hours post-transfection and centri-
fuged. Pellets were resuspended in protein lysis buffer or
RNA extraction buffer.
Cell lysates preparation
Frozen pellets of PBMC from HD mutation carriers at
premanifest, early, moderate and advanced stages and
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lated from whole blood collected in Mononuclear Cell
Preparation Tubes (CPT with sodium citrate, DB Diagnos-
tics) followed by density gradient centrifugation (1500 g,
20 minutes at room temperature). The PBMC layer was
removed and washed twice with PBS (300 g, 10 minutes at
room temperature). Cell pellets were snap-frozen and
stored at −80°C until further analysis. Five cellular pellets
from different subjects for each disease condition, (con-
taining ~1.0 106 cells, with vitality higher than 80%) were
lysed by sonication in 1 mL physiological buffer (Tris
50 mM pH 7.4, NaCl 150 mM, EDTA 1 mM) with prote-
ase inhibitors (Complete EDTA–free protease inhibitor
cocktail, Roche and PhosSTOP, phosphatase inhibitor
cocktail, Roche). Total lysates were clarified by centrifuga-
tion at 3000 g for 5 minutes and their protein amount
quantified by BCA (Piercenet) according to manifacturer’s
instructions. Clarified samples were divided into single-
use aliquots and stored frozen at −80°C. The same pro-
tocol was used to produce lysates of PBMC from rat
blood and total lysates from RL1 clone and transfected
HEK293 cells.
RNA isolation and RT-PCR
Cells were collected 24 hours post transfection and RNA
was isolated using RLT Buffer (RNeasy Plus Mini Kit,
QIAGEN GmbH, Hilden, Germany) according to manu-
facturer’s instructions. 1 μg of mRNA was retrotran-
scribed using the QuantiTect Reverse Transcription Kit
(QIAGEN) according to the manufacturer’s instructions.
For every RNA sample two independent reverse tran-
scriptase reactions were performed. Quantitative real-
time RT-PCR (RT-qPCR) was performed in triplicate for
the analyzed genes using the CFX96 Real Time System/
C1000™ Thermal Cycler (Bio-Rad). All reactions were
performed in a total volume of 20 μL containing 10 ng
cDNA, 10 μL iQ™ SYBR Green Supermix (Bio-Rad) and
0.3 mM forward and reverse primers. Amplification cy-
cles consisted of a first denaturating step at 95°C for
3 minutes, followed by 40 cycles of 30 seconds at 95°C and
30 seconds at 60°C. The amount of target gene mRNA was
normalized to RPL13a levels. Primer sequences used were




Enzyme-linked immunosorbent assay (ELISA)
ELISA assay for HTT quantification was performed on
Nunc MaxiSorp 96-well ELISA plates (Thermo Scientific).
The plates were coated overnight at 4°C with 100 μL/well
of monoclonal mouse anti-HTT (clone HDB4E10, AbD
Serotec, Bio-Rad lab, Inc.) antibody freshly diluted at
1 μg/mL in PBS. Plates were then washed three times inPBS with 0.1% Tween 20 (ELISA-washing buffer) and
blocked with 300 μL/well of BSA 1% in PBS (ELISA-
blocking buffer) for 30 minutes at room temperature.
Standard HTT-Q138 protein and analytes were diluted in
blocking buffer (100 μL final volume), added to the wells
and incubated for 90 minutes at room temperature. After
three washing steps, rabbit anti-HTT (clone EP867Y,
Abcam plc, Cambridge, UK) was used as detection anti-
body diluted at 1 μg/mL in blocking buffer (100 μL/well)
and incubated at room temperature for 60 minutes. After
washing steps the immunocomplex was detected using an
anti-rabbit IgG (H+ L) HRP conjugated (Bio-Rad) anti-
body diluted 1:5000 in blocking buffer and incubated at
room temperature for 60 minutes. After six washing steps
100 μL/well of TMB substrate (Sigma Aldrich) were added
and colorimetric reaction was stopped after 10 minutes
adding 100 μL/well of stop solution (Sigma Aldrich). The
absorbance signals were read at 450 nm in Safire2 plate
reader (Tecan Trading AG, Switzerland). A similar pro-
cedure was applied during assay development using dif-
ferent capture/detection antibodies and in optimization
experiments. In cell lysates analysis, soluble HTT content
in unknown samples, loaded in triplicate, was calculated
through a standard curve (four parameter sigmoid model -
IDBS XLfit4™) built by ten serial dilutions of HTT-Q138
from 1x10-2 to 2x103 ng per well and loaded on the plate
in duplicate. Standard calibrators having technical repli-
cates with %CV higher than 10% were discarded from the
fitting.
Mass spectrometry and protein database search
HTT-Q138 purity was confirmed by MS/MS analysis
performed at Proteome Sciences plc (United Kingdom).
Protein identity was confirmed by MS/MS analysis.
The purified HTT-Q138, separated by mono-dimensional
SDS-PAGE, was in-gel digested using trypsin, endoprotei-
nase Glu-C and chymotrypsin. Digests were analyzed
using an electrospray (ESI) LTQ-Orbitrap mass spectrom-
eter (Thermo Fisher Scientific) after reversed-phase nano
liquid chromatography separation. A data-dependant ac-
quisition method was used on top twenty ions selected
after an MS survey scan. Selected ions were analyzed by
MS/MS in the LTQ using collision-induced dissociation.
Collected data were converted into peak lists and searched
against protein databases using Mascot (Matrix Science
Science Inc. MA, USA) through the Proteome Discoverer
(Thermo Fisher Scientific) interface. Searches were per-
formed in SwissProt and HTT-Q138 protein database
built according to the Vector NTI file sequence carrying
the 3XFLAG at the N-terminus of the protein.
Statistical analysis
Pharmacological validation experiments data (HTT-ELISA
and qPCR), were normalized on control sample in each
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lysis was applied on normalized values by using a two-way
ANOVA model considering transfection and treatment as
independent variables. For qPCR data, statistical analysis
was performed on logarithmic transformed HTT rela-
tive expression values additionally normalized on con-
trol samples.
HTT quantities measured in human PBMC from HD
patients matched with healthy volunteers were analyzed
using a one-way ANOVA considering, for each subject,
average values obtained from the three technical repli-
cates normalized by the total protein content. Where ap-
propriate, post-hoc comparisons were performed with
Bonferroni test.
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